China’s New Essential Drug List Adds Drugs For Major Diseases, But Pricing, Market Pressure Likely To Increase
This article was originally published in PharmAsia News
Executive Summary
China adds 14 new oncology drugs to its newly revised Essential Drug List, as well as human insulins and hemophilia agents for the first time. Notable MNC drugs include Pfizer’s Norvasc, Novartis’ Diovan, Sanofi’s blood thinner Plavix and Bayer’s Glucobay.
You may also be interested in...
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.